Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Aly-Khan A. Lalani

McMaster University

Canada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Canada

Articles (31)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (12)

Avirup Guha

Director of Cardio-Oncology

Augusta University

UNITED STATES

View details

Scott Morgan

Associate Professor

University of Ottawa

CANADA

View details

Andrea Necchi

Associate Professor

Vita-Salute San Raffaele University

ITALY

View details

Michael Ong

University of Ottawa

CANADA

View details

Eric Rupe

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Guillermo de Velasco

Hospital Universitario 12 de Octubre

SPAIN

View details

Gregory Pond

McMaster University

CANADA

View details

Christopher J.D. Wallis

CANADA

View details

Niki Zacharias Millward

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Anand Swaminath

juravinski cancer centre mcmaster university hamilton ontario canada

CANADA

View details

Bradley McGregor

Dana-Farber Cancer Institute

UNITED STATES

View details

Sebastien Hotte

McMaster University

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aly-Khan A. Lalani

Research Interests

Make your next move.

Explore related searches

Articles (31)

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity

Letter: Urology Publication Output in Potentially Predatory Journals From 2019 to 2024

Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

Comparison of partial nephrectomy to radical nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian Multi-Institutional Collaborative

Identifying Patients With Prostate Cancer Who Benefit Most From Routine Cardiovascular Specialist Referral

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma

Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.

Prostate-specific antigen outcomes of darolutamide and androgen deprivation therapy in patient subgroups by age, comorbidities, and concomitant medications: ARANOTE post hoc analyses.

Real-world management strategies and outcomes of brain metastases in patients with mRCC.

Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World Analysis

Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis

IP73-14 UROLOGIST-LEVEL VARIATION IN ANDROGEN DEPRIVATION THERAPY INTENSIFICATION IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A RETROSPECTIVE, POPULATION-BASED COHORT STUDY IN ONTARIO, CANADA

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma

Node Positive Resected Renal Cell Carcinoma Portends a Poor Prognosis: Results From the Canadian Kidney Cancer Collaboration

Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada

Real-World effectiveness of second-line cabozantinib in metastatic renal cell carcinoma in the era of immunotherapy combinations: Results from the international metastatic renal cell carcinoma database consortium (IMDC)

CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.

Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.

Efficacy and safety of belzutifan in patients with metastatic clear cell renal cell carcinoma (mccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Optimizing Treatment Selection in Advanced Renal Cell Carcinoma via IMDC Risk Group Stratification

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.

Corrigendum to “Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma” [Eur Urol 2023]

Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population.

Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.

MP41-03 IS A RENAL TUMOUR BENIGN OR MALIGNANT? A PREDICTION TOOL INCLUDING PATIENTS MANAGED WITH SURGERY, ABLATION, OR SURVEILLANCE

PD07-10 OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC cT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE

Outcomes of partial nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian multi-institutional collaborative.

Collaborators (12)

Avirup Guha

Scott Morgan

Andrea Necchi

Michael Ong

Eric Rupe

Guillermo de Velasco

Gregory Pond

Christopher J.D. Wallis

Niki Zacharias Millward

Anand Swaminath

Bradley McGregor

Sebastien Hotte

Make your next move.